Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection

[1]  Ahmed El-Shamy,et al.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. , 2014, World journal of gastroenterology.

[2]  S. Lo,et al.  Production and pathogenicity of hepatitis C virus core gene products. , 2014, World journal of gastroenterology.

[3]  V. Soriano,et al.  Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.

[4]  Yoshiyuki Suzuki,et al.  Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis , 2012, Hepatology.

[5]  R. Jaspe,et al.  Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates , 2012, Virology Journal.

[6]  Yusuke Nakamura,et al.  Impact of viral amino acid substitutions and host interleukin‐28b polymorphism on replication and susceptibility to interferon of hepatitis C virus , 2011, Hepatology.

[7]  A. Tsubota,et al.  Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C , 2011, Molecular and Cellular Biochemistry.

[8]  J. Macías,et al.  Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients , 2011, AIDS.

[9]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[10]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[11]  N. Enomoto,et al.  Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy , 2011, Hepatology international.

[12]  T. Morin,et al.  Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha‐2a plus ribavirin therapy , 2011, Journal of medical virology.

[13]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[14]  Antonio Martínez,et al.  Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Yusuke Nakamura,et al.  Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin , 2010, Hepatology.

[16]  中本 晋吾.  Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development , 2010 .

[17]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[18]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[19]  K. Chayama,et al.  Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study , 2009, Journal of Gastroenterology.

[20]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy , 2009, Intervirology.

[21]  Yoshiyuki Suzuki,et al.  A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response , 2009, Journal of medical virology.

[22]  Yoshiyuki Suzuki,et al.  Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma , 2008, Journal of medical virology.

[23]  S. Sookoian,et al.  Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment , 2008, Journal of medical virology.

[24]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.

[25]  P Martus,et al.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.

[26]  Philip Beineke,et al.  Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response , 2001, Journal of medical virology.

[27]  C. Rice,et al.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. , 1997, Science.

[28]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[29]  B. Korber,et al.  Signature pattern analysis: a method for assessing viral sequence relatedness. , 1992, AIDS research and human retroviruses.

[30]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.